[RuCl(p-cymene)-(S)-BINAP]Cl催化不对称合成反式-3-氨基-双环[2.2.2]辛烷-2-甲酸乙酯

doi:10.6023/cjoc202301029

摘要/Abstract

反式-3-氨基-双环[2.2.2]辛烷-2-甲酸乙酯是以RNA聚合酶PB2亚基作为靶点的一类抗流感新药(如匹莫地韦和ZSP1273)的关键手性片段. 目前, 该片段的市场需求量在数百公斤到吨级级别, 与之相对应的多个创新药已经处于临床研究阶段. 采用[RuCl(p-cymene)-(S)-BINAP]Cl为催化剂, 通过不对称转移氢化的方式一步构建了反式构型3-氨基-双环[2.2.2]辛烷-2-甲酸乙酯, 对映选择性最高可达98% ee以上, 从而避免了构型翻转及脱保护等工艺过程, 具备工业化放大生产的潜质与商业价值.

关键词: 流感, 钌催化, 不对称转移氢化, β-氨基酸酯

trans-3-Amino-bicyclo[2.2.2]octane-2-carboxylic acid ester is the key common chiral fragment of some novel antiviral drugs (like Pimodivir and ZSP1273), which targets the PB2 subunit of RNA polymerase. Now, the market demand of this molecule is at level of hundreds kilograms to tons, and there are several related innovative drugs in clinical study. Here a asymmetric transfer hydrogenation strategy to directly construct trans-3-amino-bicyclo[2.2.2]octane-2-carboxylic acid ethyl ester using [RuCl(p-cymene)-(S)-BINAP]Cl as catalyst with excellent enantioselectivity (over 98% ee) and without tautomerization and protecting/de-protecting process is developed, which holds the potential of scale up production and commercial value.

Key words: influenza, Ru catalysis, asymmetric transfer hydrogenation, β-amino acid ester

引用此文

周章涛, 王杨, 程冰心, 叶伟平. [RuCl(p-cymene)-(S)-BINAP]Cl催化不对称合成反式-3-氨基-双环[2.2.2]辛烷-2-甲酸乙酯[J]. 有机化学, 2023, 43(8): 2961-2967.

Zhangtao Zhou, Yang Wang, Bingxin Cheng, Weiping Ye. [RuCl(p-cymene)-(S)-BINAP]Cl Catalyzed Asymmetric Preparation of trans-3-Amino-bicyclo[2.2.2]octane-2-carboxylic Acid Ethyl Ester[J]. Chinese Journal of Organic Chemistry, 2023, 43(8): 2961-2967.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

图/表 8

参考文献 10

[1]	(a) Paules, C.; Subbarao, K. Lancet 2017, 390, 697. doi: 10.1016/S0140-6736(17)30129-0
	(b) Zhang, A. J. Chin. J. Control Endem. Dis. 2009, 24, 1. (in Chinese)
	( 张爱君, 中国地方病防治杂志, 2009, 24, 1.)
[2]	(a) Ziegler, T.; Hemphill, M. L.; Ziegler, M. L.; Perez-Oronoz, G.; Klimov, A. I.; Hampson, A. W.; Regnery, H. L.; Cox, N. J. J. Infect. Dis. 1999, 180, 935. pmid: 10479115
	(b) Deyde, V. M.; Xu, X.; Bright, R. A.; Shaw, M.; Smith, C. B.; Zhang, Y.; Shu, Y.; Gubareva, L. V.; Cox, N. J.; Klimov, A. I. J. Infect. Dis. 2007, 196, 249. doi: 10.1086/522482 pmid: 10479115
[3]	(a) Tanoury, G. J.; Nugent, W. A.; Dvornikovs, V.; Rose, P. J. WO 2015073481, 2015.
	(b) Byrn, R. A.; Jones, S. M.; Bennett, H. B.; Bral, C.; Clark, M. P.; Jacobs, M. D.; Kwong, A. D.; Ledeboer, M. W.; Leeman, J. R.; McNeil, C. F.; Murcko, M. A.; Nezami, A.; Perola, E.; Rijnbrand, R.; Saxena, K.; Tsai, A. W.; Zhou, Y.; Charifson, P. S. Antimicrob. Agents Chemother. 2015, 59, 1569. doi: 10.1128/AAC.04623-14
[4]	(a) Trevejo, J. M.; Asmal, M.; Vingerhoets, J.; Polo, R.; Robertson, S.; Jiang, Y.; Kieffer, T. L.; Leopold, L. Antiviral Ther. 2018, 23, 335. doi: 10.3851/IMP3212
	(b) Kikuchi, T.; Watanabe, A. Respir. Invest. 2019, 57, 1. doi: 10.1016/j.resinv.2018.10.002
[5]	Hu, Y.; Li, H.; Wu, M.; Zhang, H.; Ding, Y.; Yun, P.; Li, X.; Yu, Z. Expert Opin. Invest. Drugs 2021, 30, 1159. doi: 10.1080/13543784.2021.1994944
[6]	(a) Ren, Q.; Tang, C.; Yin, J.; Yi, K.; Lei, Y.; Wang, Y.; Zhang, Y. WO 2018127096, 2018.
	(b) Nti-addae, K. W.; Waldo, M.; O'Neil, S. A.; Van, A. J. G.; Macikenas, D.; Mudunuri, P.; Shi, Y.; Ledeboer, M. W.; Jurkauskas, V.; Jones, S.; Byrn, R.; Asmal, M.; Robertson, S. M.; Tsai, W. WO 2015073476, 2015.
[7]	Zhou, Z.; Huang, Z.; Chen, R.; Cui, J.; Chen, K.; Lan, T.; Ye, W.; Fei, A. WO 2021135127, 2021.
[8]	Mewald, M.; Troltsch, S.; Gellhaar, S.; cuypers, J. L. J.; Filliers, W. F. M.; Maes, T. W. L. WO 2020212399, 2020.
[9]	Strotman, N. A.; Baxter, C. A.; Brands, K. M. J.; Cleator, E.; Krska, S. W.; Reamer, R. A.; Wallace, D. J.; Wright, T. J. J. Am. Chem. Soc. 2011, 133, 8362. doi: 10.1021/ja202358f pmid: 21528938
[10]	Nie, R.; Tao, Y.; Nie, Y.; Lu, T.; Wang, J.; Zhang, Y.; Lu, X.; Xu, C. C. ACS Catal. 2021, 11, 1071. doi: 10.1021/acscatal.0c04939

Entry	Hydrogen source	Amine source	GC yield/%				ee/% of 2
Entry	Hydrogen source	Amine source	1	2	3	4	ee/% of 2
1	HCO₂NH₄	aq. NH₃•H₂O	39.4	20.7	14.5	4.3	93.8
2	HCO₂NH₄	aq. NH₄Cl	31.7	38.2	7.3	4.8	92.9
3	HCO₂NH₄	aq. NH₄Ac	32.7	36.2	8.3	5.0	89.9
4	HCO₂NH₄	NH₄Cl	13.9	43.9	3.4	8.9	86.5
5	HCO₂NH₄	NH₄Ac	22.9	25.7	9.4	10.1	88.5
6^b	HCO₂NH₄		1.0	51.1	1.0	4.1	92.7
7^c	HCO₂H/Et₃N	aq. NH₃•H₂O	44.1	21.1	11.8	2.9	58.7
8^d	HCO₂H/Et₃N	aq. NH₄Cl	24.5	52.7	2.1	2.5	79.1
9^d	HCO₂H/Et₃N	aq. NH₄Ac	1.8	53.4	1.0	5.5	70.5
10	HCO₂H/Et₃N	NH₄Cl	39.1	36.2	0.4	0.9	68.1
11	HCO₂H/Et₃N	NH₄Ac	0.4	52.8	0.2	1.4	67.1

Entry	Hydrogen source	Amine source	GC yield/%				ee/% of 2
Entry	Hydrogen source	Amine source	1	2	3	4	ee/% of 2
1	HCO₂NH₄	aq. NH₃•H₂O	39.4	20.7	14.5	4.3	93.8
2	HCO₂NH₄	aq. NH₄Cl	31.7	38.2	7.3	4.8	92.9
3	HCO₂NH₄	aq. NH₄Ac	32.7	36.2	8.3	5.0	89.9
4	HCO₂NH₄	NH₄Cl	13.9	43.9	3.4	8.9	86.5
5	HCO₂NH₄	NH₄Ac	22.9	25.7	9.4	10.1	88.5
6^b	HCO₂NH₄		1.0	51.1	1.0	4.1	92.7
7^c	HCO₂H/Et₃N	aq. NH₃•H₂O	44.1	21.1	11.8	2.9	58.7
8^d	HCO₂H/Et₃N	aq. NH₄Cl	24.5	52.7	2.1	2.5	79.1
9^d	HCO₂H/Et₃N	aq. NH₄Ac	1.8	53.4	1.0	5.5	70.5
10	HCO₂H/Et₃N	NH₄Cl	39.1	36.2	0.4	0.9	68.1
11	HCO₂H/Et₃N	NH₄Ac	0.4	52.8	0.2	1.4	67.1

Entry	Hydrogen source	Additive	Conversation/% of 3	GC yield/% of 2	ee/% 2
1	HCO₂NH₄		98.1	74.4	98.0
2	HCO₂NH₄	NH₄Cl	99.0	86.0	97.4
3	HCO₂H/Et₃N	NH₄Cl	99.0	61.1	96.0
4	HCO₂NH₄	HCO₂H	97.6	71.7	92.5
5	HCO₂NH₄	AcOH	99.0	75.6	82.5
6^b	HCO₂NH₄	HCl	96.1	61.2	88.3
7	HCO₂NH₄	PhCO₂H	91.0	61.2	39.0
8^c	HCO₂NH₄	NH₄Cl	99.0	85.0	97.3

Entry	Hydrogen source	Additive	Conversation/% of 3	GC yield/% of 2	ee/% 2
1	HCO₂NH₄		98.1	74.4	98.0
2	HCO₂NH₄	NH₄Cl	99.0	86.0	97.4
3	HCO₂H/Et₃N	NH₄Cl	99.0	61.1	96.0
4	HCO₂NH₄	HCO₂H	97.6	71.7	92.5
5	HCO₂NH₄	AcOH	99.0	75.6	82.5
6^b	HCO₂NH₄	HCl	96.1	61.2	88.3
7	HCO₂NH₄	PhCO₂H	91.0	61.2	39.0
8^c	HCO₂NH₄	NH₄Cl	99.0	85.0	97.3

Entry	Catalyst loading/mol%	Conversion/% of 3	GC yield/% of 2	ee/% of 2
1^b	5.0	99.0	86.0	98.0
2^b	4.0	84.3	62.3	97.4
3^b	3.0	78.9	57.1	97.5
4^b	2.0	64.6	36.4	99.0
5^c	2.5	99.9	86.3	97.4
6^c	2.0	99.9	86.0	97.4
7^c	1.5	93.1	79.6	97.8
8^c	1.0	91.1	74.8	97.5
9^c	0.5	30.1	5.9	99.0